GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study
Study of an Endovascular Device for Aortic Disease
Raghu Motaganahalli, MD
Primary Investigator
Brief description of study
This study aims to confirm that the benefit-risk assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) remains positive in real-world use and to ensure the adequacy of the TAMBE Device training program.
Detailed description of study
This study is prospective, single-arm, multicenter post-market study designed to collect clinical outcomes data from subjects who have been treated with the TAMBE Aortic Component at up to sixty (60) clinical investigative sites (referred to as “sites” for the
remainder of the document) in the United States (U.S.).
This study will enroll a minimum of 300 subjects receiving the TAMBE Aortic Component during the endovascular repair of an aortic disease involving the visceral vessels.
Subjects will be evaluated post-implantation and will have follow-up at 1 month, 6 months, 12 months and annually thereafter through 10 years post implant.
A minimum of 100 surviving subjects with evidence of continued study participation will be available at 5 years
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Abdominal Aortic Aneurysm
-
Age: 18 years - 100 years
-
Gender: All
Inclusion Criteria:
The subject is / has:
- Treated with the aortic component of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Aortic Component) to allow endovascular repair of an aortic disease involving the visceral vessels.
- Age ≥18 years at the time of informed consent signature.
- An Informed Consent Form signed by subject or legal representative.
Exclusion Criteria:
The subject is / has:
- Any contraindications for the TAMBE Device according to the IFU.
- Planned parallel grafting with the TAMBE Aortic Component.
- Intent to modify TAMBE Aortic Component (e.g., in situ fenestration).
This study investigates the use of an endovascular device for treating aortic disease involving the visceral vessels. Aortic disease can affect the large blood vessel that carries blood from the heart to the rest of the body. The purpose of this study is to ensure the device's safety and effectiveness in a real-world setting.
Participants who receive the device will be evaluated after the procedure and followed up at regular intervals. This includes visits at 1 month, 6 months, 12 months, and yearly up to 10 years after the device is implanted. The study will gather data from multiple locations across the United States.
- Who can participate: Adults aged 18 and over who have been treated with the endovascular device for aortic disease involving the visceral vessels may participate. Participants must have signed an informed consent form.
- Study details: Participants will receive the endovascular device as part of their treatment for aortic disease. They will be monitored over time to collect data on the device's performance and safety.
- Study timelines and visits: The study will last 10 years. The study requires 5 visits.